Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report

Morten Bahrt Haulrig; Signe Ledou Nielsen; Jesper Elberling; Lone Skov

doi:10.1002/ccr3.5368

Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report

Clin Case Rep. 2022 Mar 8;10(3):e05368. doi: 10.1002/ccr3.5368. eCollection 2022 Mar.

Authors

Morten Bahrt Haulrig¹, Signe Ledou Nielsen², Jesper Elberling¹, Lone Skov^{1

3}

Affiliations

¹ Department of Dermatology and Allergy Herlev and Gentofte Hospital University of Copenhagen Hellerup Denmark.
² Department of Pathology, Herlev and Gentofte Hospital University of Copenhagen Herlev Denmark.
³ Copenhagen Research Group for Inflammatory Skin (CORGIS) Hellerup Denmark.

Abstract

Linear IgA/IgG bullous dermatosis (LAGBD) is a rare, autoimmune blistering skin disease. We report a case of LAGBD in a 70-year-old woman. All common treatments were discontinued due to side effects or lack of treatment response. The patient was successfully treated with omalizumab which cleared her lesions after three months.

Keywords: linear IgA bullous dermatosis; linear IgA/IgG bullous dermatosis; omalizumab; xolair.

Publication types

Case Reports